Sunday, December 02, 2018 8:40:40 PM
Well now allow me to post a Quote From Nasrat, The CEO of Elite per SA:
"Two months ago, in September, Elite filed a generic APAP with Codeine. The total brand and generic market for APAP with Codeine is about $45 million and our PDUFA date is July of 2019. We filed two other ANDAs earlier this year. One is the ANDA of an immediate release CNS product that we co-developed with our partner SunGen, for which there is a brand and generic sales of approximately $400 million.
Elite is hopeful that this product will be approved in December of this year. That is our PDUFA date. We will wait to hear from FDA. The second ANDA is an extended release CNS product that we co-developed with our partner SunGen. The brand and generic sales of that product, the extended release version is $1.6 billion."
So am I to ascertain that Nasrat The CEO of Elite does not know what he is speaking of in the TWO references to ANDA PDUFA dates above !!!!!!!!!!!!
LoL LoL,
IB_ ;)
"Two months ago, in September, Elite filed a generic APAP with Codeine. The total brand and generic market for APAP with Codeine is about $45 million and our PDUFA date is July of 2019. We filed two other ANDAs earlier this year. One is the ANDA of an immediate release CNS product that we co-developed with our partner SunGen, for which there is a brand and generic sales of approximately $400 million.
Elite is hopeful that this product will be approved in December of this year. That is our PDUFA date. We will wait to hear from FDA. The second ANDA is an extended release CNS product that we co-developed with our partner SunGen. The brand and generic sales of that product, the extended release version is $1.6 billion."
So am I to ascertain that Nasrat The CEO of Elite does not know what he is speaking of in the TWO references to ANDA PDUFA dates above !!!!!!!!!!!!
LoL LoL,
IB_ ;)
SHOW ME THE MONEY OR SHUT UP !!
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
